JP2020510678A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510678A5
JP2020510678A5 JP2019548677A JP2019548677A JP2020510678A5 JP 2020510678 A5 JP2020510678 A5 JP 2020510678A5 JP 2019548677 A JP2019548677 A JP 2019548677A JP 2019548677 A JP2019548677 A JP 2019548677A JP 2020510678 A5 JP2020510678 A5 JP 2020510678A5
Authority
JP
Japan
Prior art keywords
compound
muscle
formula
disease
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019548677A
Other languages
English (en)
Japanese (ja)
Other versions
JP7761372B2 (ja
JP2020510678A (ja
Filing date
Publication date
Priority claimed from GBGB1703736.7A external-priority patent/GB201703736D0/en
Priority claimed from GBGB1706596.2A external-priority patent/GB201706596D0/en
Priority claimed from GBGB1707863.5A external-priority patent/GB201707863D0/en
Application filed filed Critical
Priority claimed from PCT/EP2018/055790 external-priority patent/WO2018162651A1/en
Publication of JP2020510678A publication Critical patent/JP2020510678A/ja
Publication of JP2020510678A5 publication Critical patent/JP2020510678A5/ja
Priority to JP2023076856A priority Critical patent/JP2023100870A/ja
Application granted granted Critical
Publication of JP7761372B2 publication Critical patent/JP7761372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019548677A 2017-03-08 2018-03-08 対象におけるマイトファジーを改善するための方法 Active JP7761372B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023076856A JP2023100870A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1703736.7A GB201703736D0 (en) 2017-03-08 2017-03-08 Methods for improving mitophagy in subjects
GB1703736.7 2017-03-08
GB1706596.2 2017-04-25
GBGB1706596.2A GB201706596D0 (en) 2017-04-25 2017-04-25 Methods for improving mitophagy in subjects
GB1707863.5 2017-05-16
GBGB1707863.5A GB201707863D0 (en) 2017-05-16 2017-05-16 Methods for improving mitophagy in subjects
PCT/EP2018/055790 WO2018162651A1 (en) 2017-03-08 2018-03-08 Methods for improving mitophagy in subjects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076856A Division JP2023100870A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Publications (3)

Publication Number Publication Date
JP2020510678A JP2020510678A (ja) 2020-04-09
JP2020510678A5 true JP2020510678A5 (https=) 2021-04-22
JP7761372B2 JP7761372B2 (ja) 2025-10-28

Family

ID=61691937

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019548677A Active JP7761372B2 (ja) 2017-03-08 2018-03-08 対象におけるマイトファジーを改善するための方法
JP2023076856A Pending JP2023100870A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023076856A Pending JP2023100870A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Country Status (4)

Country Link
US (1) US11969408B2 (https=)
EP (2) EP3592425A1 (https=)
JP (2) JP7761372B2 (https=)
WO (1) WO2018162651A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4233858T3 (da) 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
US20180256538A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Method for improving mitophagy in subjects
US20180256471A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Skin Treatment Methods
GB201916046D0 (en) * 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
CA3206062A1 (en) 2021-01-27 2022-08-04 Said Oumouch Urolithin derivatives and methods of use thereof
JP2022185501A (ja) * 2021-06-02 2022-12-14 株式会社ダイセル 閉経後の女性の筋肉の重量を増加させるための組成物
EP4452259A1 (en) * 2021-12-20 2024-10-30 Société des Produits Nestlé S.A. Compositions comprising urolithin for treating muscle decline and a kidney dysfunction
JP2025510123A (ja) 2022-03-22 2025-04-14 アマゼンティス エスアー 組成物
CA3258478A1 (en) * 2022-06-06 2023-12-14 Amazentis Sa Urolithines to improve heart function and health
AU2024279527A1 (en) * 2023-05-26 2026-01-15 Amazentis Sa Urolithin for improving performance in elite and sub-elite athletes
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
WO2024252410A1 (en) * 2023-06-09 2024-12-12 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive composition for enhancing activity of pink1/parkin pathway
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02304080A (ja) 1989-05-17 1990-12-17 Toyo Pharma- Kk ６Ｈ―ジベンゾ［ｂ，ｄ］ピラン―６―オン誘導体，その製法及び用途
KR20000019718A (ko) 1998-09-15 2000-04-15 박호군 탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물
US20030078212A1 (en) 1998-10-30 2003-04-24 Jia-He Li Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same
US7727563B2 (en) 1999-04-19 2010-06-01 Pom Wonderful, Llc Methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans
US7611738B2 (en) 2005-05-24 2009-11-03 Pom Wonderful, Llc Processes for extracting phytochemicals from pomegranate solids and compositions and methods of use thereof
US20010047032A1 (en) 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
US6440436B1 (en) 2001-05-18 2002-08-27 Natreon Inc. Process for preparing purified shilajit composition from native shilajit
US20080039179A1 (en) 2001-06-27 2008-02-14 Seelig Jerald C Gaming display with moveable indicator and methods of use
WO2004073612A2 (en) * 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
ES2543981T3 (es) 2004-03-24 2015-08-26 The Regents Of The University Of California Purificaciones de elagitaninos
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
US20060257337A1 (en) 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
BRPI0708318A2 (pt) 2006-02-28 2011-05-24 Paloma Pharmaceuticals, Inc. composições e uso de compostos para tratar doenças caracterizadas por proliferação celular e angiogênese
WO2007127263A2 (en) 2006-04-26 2007-11-08 The Regents Of The University Of California Therapeutic uses of urolithins
US8894993B2 (en) 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
US8017147B2 (en) 2008-04-07 2011-09-13 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
US8367072B2 (en) 2006-12-08 2013-02-05 Polifenoles Naturales, S.L. Composition for treating obesity and method of using the same
US7972633B2 (en) 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
WO2008139123A2 (fr) 2007-05-11 2008-11-20 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
EP2033526A1 (en) 2007-09-07 2009-03-11 Probelte Pharma, S.A. Nutritional products comprising pomegranate extracts containing ellagitannins and their use
US20110021618A1 (en) 2008-03-25 2011-01-27 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
US7927633B2 (en) 2008-03-28 2011-04-19 Janiece Diane Swilling Adaptogenic tea
WO2009137859A1 (en) * 2008-05-15 2009-11-19 Alois Jungbauer Compounds for the treatment of metabolic syndrome and insulin resistance
WO2009153652A2 (en) 2008-06-19 2009-12-23 Avesthagen Limited An extract and a process thereof (pomplex)
US20100004334A1 (en) 2008-07-01 2010-01-07 Mead Johnson Nutrition Company Nutritional Compositions Containing Punicalagins
CN101301319A (zh) 2008-07-09 2008-11-12 中国科学院新疆理化技术研究所 石榴花多酚的制备方法及其应用
US20100055247A1 (en) 2008-08-29 2010-03-04 Tirrito Salvatore J Nutritional Compositions for Athletes
JP5385686B2 (ja) 2009-06-05 2014-01-08 サントリーホールディングス株式会社 血小板凝集抑制剤
WO2011011721A2 (en) 2009-07-24 2011-01-27 Amazentis Sa Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
JP6054301B2 (ja) 2010-12-23 2017-01-11 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
WO2012113835A1 (en) 2011-02-22 2012-08-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection
DK4233858T3 (da) 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
GB201323008D0 (en) 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
US20180256538A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Method for improving mitophagy in subjects
US20180256471A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Skin Treatment Methods

Similar Documents

Publication Publication Date Title
JP2020514338A5 (https=)
JP2020510678A5 (https=)
AU2023219852B2 (en) Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US11969411B2 (en) Administration of berberine metabolites
EP3426240B1 (en) Mixed salt compositions for producing elevated and sustained ketosis
EP3873442B1 (en) A composition for weigth loss or weight management comprising beta-hydroxybutyrate and cannabidiol
EP1699449B1 (en) Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
JP2023100869A5 (https=)
JP5714227B2 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
JP2023100870A5 (https=)
KR20180100455A (ko) 영양 조성물
CN101842103A (zh) 用于脑部健康的单位剂量
US20250302782A1 (en) Administration of beta-hydroxybutyrate and related compounds in humans for the treatment and/or prevention of respiratory illnesses
CN105828623B (zh) 富含芝麻素类的组合物
US8722013B2 (en) Use of R(+)-alpha-lipoic acid for cryptogenic neuropathy
US20170035728A1 (en) Compositions for Improved Body Composition
WO2023081409A1 (en) Administration of berberine metabolites
US12533346B2 (en) Administration of berberine metabolites
US12496283B2 (en) Administration of R-beta-hydroxybutyrate and related compounds in humans
US12171735B2 (en) Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
EP4637740A1 (en) Combinations of a urothilin and a ketone body
US20230364043A1 (en) C5 ketone compositions and related methods for therapeutic and performance supplementation
CN110139645A (zh) 用于预防和/或治疗恶病质的ω-3脂肪酸组合物
CA2842767A1 (en) Compositions of alpha-lipoic acid and curcumin for improved body composition